Dividend Capture Strategy: 5 High-Yield Stocks to Buy in February

3. Gilead Sciences, Inc. (NASDAQ:GILD)

Ex-Dividend Date: March 14
Dividend Yield as of February 6: 3.47%

Gilead Sciences, Inc. (NASDAQ:GILD) is an American biopharmaceutical company, based in California. The company specializes in the research and development of antiviral drugs. In February, Piper Sandler raised its price target on the stock to $112 with an Overweight rating on the shares, noting the company’s commercial business.

Gilead Sciences, Inc. (NASDAQ:GILD) started paying dividends in 2015 and has raised its payouts every year since then. It currently pays a quarterly dividend of $0.75 per share, raising it by 2.7% on February 2. The stock’s dividend yield on February 6 came in at 3.47% and it will go ex-dividend on March 14.

At the end of Q3 2022, 56 hedge funds tracked by Insider Monkey owned stakes in Gilead Sciences, Inc. (NASDAQ:GILD), valued at $3.63 billion collectively.

Ariel Investments mentioned Gilead Sciences, Inc. (NASDAQ:GILD) in its Q3 2022 investor letter. Here is what the firm has to say:

“At the stock level, biopharmaceutical company Gilead Sciences, Inc. (NASDAQ:GILD) was the top contributor in the quarter based on positive data released in a study evaluating Trodelvy versus comparative chemotherapy in patients with metastatic breast cancer. The detailed findings increased investor confidence the drug would receive incremental approvals for a broader range of breast cancer treatments. Shares also received a boost on news the TAF patent portfolio for HIV drugs will be extended from the middle of this decade through the early 2030s, thereby lengthening the company’s long-term opportunity in the virology market.”